

Denis Choquette

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/758768/publications.pdf>

Version: 2024-02-01

10
papers

452
citations

1307594

7
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

621
citing authors

#	ARTICLE	IF	CITATIONS
1	Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: Addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. <i>Arthritis and Rheumatism</i> , 2001, 44, 735-736.	6.7	195
2	Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. results of a multicenter randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 1993, 36, 795-803.	6.7	152
3	Total Knee Replacement as a Knee Osteoarthritis Outcome. <i>Cartilage</i> , 2013, 4, 219-226.	2.7	29
4	Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry. <i>Arthritis Research and Therapy</i> , 2019, 21, 138.	3.5	28
5	Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis: an open-label Canadian trial. <i>Clinical Rheumatology</i> , 2008, 27, 587-595.	2.2	18
6	Development of a Canadian Core Clinical Dataset to Support High-quality Care for Canadian Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1813-1822.	2.0	11
7	Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: Addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. <i>Arthritis and Rheumatism</i> , 2001, 44, 735-736.	6.7	10
8	Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry. <i>BMC Rheumatology</i> , 2020, 4, 46.	1.6	8
9	Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts. <i>Journal of Rheumatology</i> , 2022, 49, 16-25.	2.0	1
10	Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists. <i>Pharmacy Practice</i> , 2021, 19, 2377.	1.5	0